Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123>>>
61 Items
Title  Creator  Group name  Publishing year 
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas Becker et al. EquipeCTCS 2025-01-06
Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe. Tabet et al. EquipeCTCS 2025
E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development Di Michele et al. EquipeCTCS 2025-01-02
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer Bardia et al. EquipeCTCS 2024-12-05
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells Slaninová et al. EquipeAD 2024-05-14
Robotic posterior pelvic exenteration for locally advanced rectal cancer-A video vignette Colombo et al. EquipeCTCS 2024-10
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features Boissière-Michot et al. EquipeCTCS 2024
Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer Colombo et al. EquipeCTCS 2024-10
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer Massa et al. EquipeCTCS 2024-12-01
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients Puszkiel et al. EquipeCTCS 2024-08-01
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Galvin et al. EquipeCTCS 2024-01
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study Bardol et al. EquipeCTCS 2024-01
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery Houvenaeghel et al. EquipeCTCS 2024-09-27
Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2) Faravel et al. EquipeCTCS 2024-01-08
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer Eslami-S et al. EquipeCTCS 2024-01
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer Orhan et al. EquipeCTCS 2024-05-01
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment Bruciamacchie et al. EquipeCG 2024-11-29
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation Antoine et al. EquipeCTCS 2024-12
A metabolic crosstalk between liposarcoma and muscle sustains tumor growth Manteaux et al. EquipeLL 2024-09-12
The quest for the optimal biomarker: is extending the spectrum of targeted PIK3CA mutations in breast cancer carcinoma worthwhile? Quesada and Jacot EquipeCTCS 2023-10-25
Response to Somay et al. Letter to the Editor Regarding "Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy" Faravel et al. EquipeAD 2023
Multiple Fra-1-bound enhancers showing different molecular and functional features can cooperate to repress gene transcription Bejjani et al. EquipeCTCS 2023-07-18
Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR Villemin et al. EquipeJC 2023-05-05
Carcinoembryonic Antigen - Related Cell Adhesion Molecule Type 5 Receptor - Targeted Fluorescent Intraoperative Molecular Imaging Tracer for Lung Cancer: A Nonrandomized Controlled Trial Azari et al. EquipeAP 2023-01-27
Proof of concept of improved fluorescence-guided surgery of colon cancer liver metastasis using color-coded imaging of a tumor-labeling fluorescent antibody and indocyanine green restricted to the adjacent liver segment Nishino et al. EquipeAP 2022-08-01
123>>>
61 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés